期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 54
卷 54, 期 -, 页码 295-315出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-011613-135930
关键词
fetus; placenta; risks; teratology; biomarkers
资金
- Canadian Institutes of Health Research Funding Source: Medline
Pregnant women are almost always excluded from randomized controlled clinical trials, as the risks to the fetus posed by most new chemical entities or approved drugs cannot be sufficiently ruled out. Hence, a major scientific challenge in this field is to discover and validate alternative tools that will fill the knowledge gap created by the lack of participation in gold-standard randomized trials. This review focuses on novel tools that allow estimation of fetal risks after exposure to therapeutic agents, such as placental perfusion studies, biomarkers of fetal exposure, and novel epidemiological and pharmacogenetic tools, all of which have been tested successfully in recent years.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据